Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

por Earle, C C, Evans, W K
Publicado 1999

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

por Evans, W. K., Will, B. P., Berthelot, J. M., Wolfson, M. C.
Publicado 1995

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

por Will, B P, Petit, C Le, Berthelot, J-M, Tomiak, E M, Verma, S, Evans, W K
Publicado 1999

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.

por Evans, W. K., Eisenhauer, E., Hughes, P., Maroun, J. A., Ayoub, J., Shepherd, F. A., Feld, R.
Publicado 1988

First do no harm: extending the debate on the provision of preventive tamoxifen

por Will, B P, Nobrega, K M, Berthelot, J-M, Flanagan, W, Wolfson, M C, Logan, D M, Evans, W K
Publicado 2001

A prospective study of peri-diagnostic and surgical wait times for patients with presumptive colorectal, lung, or prostate cancer

por Grunfeld, E, Watters, J M, Urquhart, R, O'Rourke, K, Jaffey, J, Maziak, D E, Morash, C, Patel, D, Evans, W K
Publicado 2009

Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review

por Eng, L., Brual, J., Nagee, A., Mok, S., Fazelzad, R., Chaiton, M., Saunders, D.P., Mittmann, N., Truscott, R., Liu, G., Bradbury, P.A., Evans, W.K., Papadakos, J., Giuliani, M.E.
Publicado 2022

Cancer diagnostic assessment programs: standards for the organization of care in Ontario

por Brouwers, M., Oliver, T.K., Crawford, J., Ellison, P., Evans, W.K., Gagliardi, A., Lacourciere, J., Lo, D., Mai, V., McNair, S., Minuk, T., Rabeneck, L., Rand, C., Ross, J., Smylie, J., Srigley, J., Stern, H., Trudeau, M.
Publicado 2009